- Report
- August 2025
- 186 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- August 2025
- 191 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- November 2025
- 195 Pages
Global
From €3156EUR$3,545USD£2,758GBP
€3507EUR$3,939USD£3,064GBP
- Report
- November 2025
- 200 Pages
Global
From €5662EUR$6,360USD£4,948GBP
€7078EUR$7,950USD£6,185GBP
- Report
- September 2025
- 250 Pages
Global
From €3997EUR$4,490USD£3,493GBP
- Report
- June 2025
- 400 Pages
Global
From €4406EUR$4,949USD£3,850GBP
- Report
- September 2025
- 91 Pages
Global
From €3500EUR$4,211USD£3,166GBP
- Report
- August 2022
- 110 Pages
Global
From €4229EUR$4,750USD£3,695GBP
- Report
- April 2024
- 82 Pages
United States
From €3116EUR$3,500USD£2,723GBP
Icatibant is a type of cardiovascular drug used to treat acute attacks of hereditary angioedema (HAE). It is a synthetic peptide that works by blocking the action of bradykinin, a chemical that causes swelling in the body. Icatibant is administered as a subcutaneous injection and is available in both pre-filled syringes and auto-injectors. It is used to treat acute attacks of HAE in adults and children over the age of 12.
Icatibant is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2011. It is currently marketed by Shire Pharmaceuticals, a subsidiary of Takeda Pharmaceuticals. Other companies involved in the market include CSL Behring, Pharming Technologies, and ViroPharma. Show Less Read more
